🇺🇸 FDA

Company profile · Sponsor

Kyverna

Kyverna Therapeutics

KYTX · NYSE biotech EMERYVILLE, CA, USA
Pipeline
14
Drugs
0
Patents
2

Quick answer

Kyverna (KYTX) is a biotech company. headquartered in EMERYVILLE, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 2 patents to this profile..

Company facts

Ticker KYTX
Exchange NYSE
Company type biotech
Headquarters EMERYVILLE, CA, USA
SEC CIK 0001994702

Pipeline (14)

Search pipeline →

  1. KYV-101

    Kyverna

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  2. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  3. Standard of Care Treatment

    Kyverna

    Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna

    Lupus Nephritis

    phase 2 other active

    1 trial

  5. KYV-101

    Kyverna

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  6. KYV-101

    Kyverna

    Systemic Sclerosis

    phase 2 mab active

    1 trial

  7. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna

    Lupus Nephritis

    phase 2 mab active

    2 trials

  8. KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

    Kyverna

    ANCA-IgG-positive ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  9. KYV101

    Kyverna

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  10. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  11. Standard lymphodepletion regimen

    Kyverna

    Stiff-Person Syndrome

    phase 2 mab active

    1 trial

  12. KYV-101

    Kyverna

    Idiopathic Inflammatory Myopathies

    phase 1 small molecule active

    1 trial

  13. KYV-101 (Biological) - 0.33 ×10^8 cells

    Kyverna

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  14. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna

    Multiple Sclerosis

    phase 1 mab active

    1 trial

Patents (2)

Search patents →

  1. US 11879003

    Methods for increasing T-cell function

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11446357

    Method for treating disease using FOXP3+CD4+ T cells

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Kyverna?

Kyverna (KYTX) is a biotech company. headquartered in EMERYVILLE, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 2 patents to this profile..

What pipeline programs does Kyverna sponsor?

We track 14 ClinicalTrials.gov-linked programs for Kyverna, including KYV-101 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Kyverna company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.